Abstract:

A61L 27/26 (2006.01)  A61F 2/28 (2006.01)

A61L 27/26 (2006.01)  A61F 2/28 (2006.01)

Agents:  LLOYD, Jeff et al; Saliwanchik, Lloyd & Enenschenk, PO Box 142950, Gainesville, FL 32614-2950 (US).

Inventors:  CHING, Jessica, A.; 3 Mcalpine Street, #502, Toronto, Ontario, M5R 3T5 (CA).  FORD, Jonathan, Michael; 2 Tampa General Circle, STC 7027, Tampa, FL 33606 (US).  DECKER, Summer Joy; 521 Winterside Drive, Apollo Beach, FL 33752 (US).


International Patent Classification:

A61L 27/26 (2006.01)  A61F 2/28 (2006.01)


Published:

— with international search report (Art. 21(3))

Title:  OSTEOCONDUCTIVE AND OSTEOINDUCTIVE IMPLANT FOR AUGMENTATION, STABILIZATION, OR DEFECT RECONSTRUCTION

Abstract:  Aspects of the present invention provide implants for augmentation, stabilization, or defect reconstruction of bone tissue, comprising a scaffold portion structured to provide shape to the implant, the scaffold portion comprising one or more of the following: one or more polylactic acid isomer; one or more polyglycolic acid isomer; and/or allogenic bone material, or similar compound.
DESCRIPTION

OSTEOCONDUCTIVE AND OSTEOINDUCTIVE IMPLANT FOR AUGMENTATION, STABILIZATION, OR DEFECT RECONSTRUCTION

BACKGROUND OF THE INVENTION

Bone allografts, polylactic acid isomers, and polyglycolic acid isomers have established independent efficacy in the treatment of bone defects and bone reconstruction in multiple clinical situations; however, there are currently no structural implants that offer osteoconductive and osteoinductive capabilities.

BRIEF SUMMARY OF THE INVENTION

Aspects of the present invention combine allogenic bone material, such as, e.g., demineralized bone matrix or bone allograft; polylactic acid (PLA) isomers; and polyglycolic acid (PGA) isomers, or similar compounds, such as, for example, a mixture of PLA and PGA polymers (PLGA polymer) or polydioxanone (PDS) into a single implant both in plate configurations and in three-dimensional (3D) configurations, whether as a predetermined standard arrangement or customized form. Implants of the present invention address skeletal reconstruction through replacing, augmenting, or buttressing the patient’s native bone.

In one aspect, the present invention provides implants for augmentation, stabilization, or defect reconstruction of bone tissue, comprising a scaffold portion structured to provide shape to the implant, the scaffold portion comprising one or more of the following: one or more polylactic acid isomer (or similar compound); one or more polyglycolic acid isomer (or similar compound); and allogenic bone material (or similar compound).

In some embodiments, the allogenic bone material comprises demineralized bone matrix.

In some embodiments, the scaffold portion is in the form of a mesh or lattice structure, or a combination of both.

In some embodiments, the implant further comprises an autologous bone graft embedded within the scaffold portion. In other embodiments, the implant further comprises bone morphogenic protein embedded within the scaffold portion.
In another aspect, the present invention provides methods for augmentation, stabilization, or defect reconstruction of bone tissue, comprising applying an implant as described herein to a site in need of augmentation, stabilization, or defect reconstruction of bone tissue.

The implants and processes herein described can be used in connection with pharmaceutical, medical, and veterinary applications, as well as fundamental scientific research and methodologies, as would be identifiable by a skilled person upon reading of the present disclosure. These and other objects, features, and advantages of the present invention will become clearer when the drawings as well as the detailed description are taken into consideration.

BRIEF DESCRIPTION OF THE DRAWINGS

For a fuller understanding of the nature of the present invention, reference should be had to the following detailed description taken in connection with the accompanying figures.

Figure 1 shows an implant of the present invention providing stabilization of a long bone.

Figure 2 shows an implant of the present invention being utilized to provide chin augmentation.

Figure 3 shows an implant of the present invention placed in position for zygoma reconstruction viewed from the face of the skull.

Figure 4 shows the implant shown in Figure 3 viewed from the side of the skull.

DETAILED DESCRIPTION OF THE INVENTION

Aspects of the present invention are directed to implants and related methods of utilizing such implants for the treatment of bone defects or for bone reconstruction.

Several aspects of the invention are described below, with reference to examples for illustrative purposes only. It should be understood that numerous specific details, relationships, and methods are set forth to provide a fuller understanding of the invention. One having ordinary skill in the relevant art, however, will readily recognize that the invention can be practiced without one or more of the specific details or practiced with other methods, protocols, reagents, cell lines, and animals. The present invention is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and/or
concurrently with other acts or events. Furthermore, not all illustrated acts, steps, or events are required to implement a methodology in accordance with the present invention. Some of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art.

Unless otherwise defined, all terms of art, notations, and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and/or as otherwise defined herein.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the indefinite articles "a," "an," and "the" should be understood to include plural reference unless the context clearly indicates otherwise.

The phrase "and/or," as used herein, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases.

As used herein, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating a listing of items, "and/or" or "or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number of items, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." As used herein, the terms "including," "includes," "having," "has," "with," or variants thereof, are intended to be inclusive similar to the term "comprising."
As would be understood by those of skill in the art, the implants and methods of the various aspects of the present invention are applicable to augmentation, stabilization, or defect reconstruction of bone tissue.

In one aspect, the present invention provides implants for augmentation, stabilization, or defect reconstruction of bone tissue, comprising a scaffold portion structured to provide shape to the implant, the scaffold portion comprising one or more of the following: one or more polylactic acid (PLA) isomer, or similar compound; one or more polyglycolic acid (PGA) isomer, or similar compound; and/or allogenic bone material, or similar compound. The compounds may be combined in varying ratios depending on the desires or needs of the clinical situation, allowing for a significant amount of customization. The mixture ratios and mesh densities are variable based on what part of the body is being repaired or augmented. The location and any potential forces that might act upon the implant are taken into consideration by the clinician. For example, a looser mesh geometry is workable in a chin or cheek implant; long bones or load bearing bones require a denser mesh for more support. These ratios may be determined by the clinician on a case by case basis depending on the treatment goals and needs of the patient and scenario, and the ratios are readily determinable by one skilled in the art. As such, the scaffold portion can comprise a single compound or multiple compounds depending on the benefits and drawbacks of each compound when used in a particular ratio and/or position in the body, which is a matter of design choice by the clinician on a case by case basis.

In some embodiments, one or more polylactic acid (PLA) isomer, or similar compound, comprises about 10%; about 20%>; about 30%>; about 40%>; about 50%>; about 60%; about 70%; about 80%; about 90%; about 100%; 0% to about 100%; about 1% to about 100%; about 10% to about 100%; about 20% to about 100%; about 30% to about 100%; about 40% to about 100%; about 50% to about 100%; about 60% to about 100%; about 70% to about 100%; about 80% to about 100%; about 90% to about 100%; 0% to about 90%; about 10% to about 80%; about 20% to about 70%; about 30% to about 60%; about 40% to about 50%; 0% to about 80%; 0% to about 70%; 0% to about 60%; 0% to about 50%; 0% to about 40%; 0% to about 30%; 0% to about 20%; 0% to about 10%; or 0% of the implant.

In some embodiments, the one or more polyglycolic acid (PGA) isomer, or similar compound, comprises about 10%>; about 20%>; about 30%>; about 40%>; about 50%>; about 60%; about 70%; about 80%; about 90%; about 100%; 0% to about 100%; about 1% to about 100%; about 10% to about 100%; about 20% to about 100%; about 30% to about 100%;
about 40% to about 100%; about 50% to about 100%; about 60% to about 100%; about 70% to about 100%; about 80% to about 100%; about 90% to about 100%; 0% to about 90%; about 10% to about 80%; about 20% to about 70%; about 30% to about 60%; about 40% to about 50%; 0% to about 80%; 0% to about 70%; 0% to about 60%; 0% to about 50%; 0% to about 40%; 0% to about 30%; 0% to about 20%; 0% to about 10%; or 0% of the implant.

In some embodiments, the allogenic bone material, or similar compound, comprises about 10%; about 20%; about 30%; about 40%; about 50%; about 60%; about 70%; about 80%; about 90%; about 100%; 0% to about 100%; 1% to about 100%; about 10% to about 100%; about 20% to about 100%; about 30% to about 100%; about 40% to about 100%; about 50% to about 100%; about 60% to about 100%; about 70% to about 100%; about 80% to about 100%; about 90% to about 100%; 0% to about 90%; about 10% to about 80%; about 20% to about 70%; about 30% to about 60%; about 40% to about 50%; 0% to about 80%; 0% to about 70%; 0% to about 60%; 0% to about 50%; 0% to about 40%; 0% to about 30%; 0% to about 20%; 0% to about 10%; or 0% of the implant.

In some embodiments, the allogenic bone material comprises demineralized bone matrix (DBM). Alternative compounds that can be used in place of, or in combination with, DBM include hydroxyapatite, calcium sulfate, beta tricalcium phosphate, recombinant human bone morphogenetic proteins, bioactive glass, and combinations thereof.

PLA and PGA isomers offer in situ malleability with warming, provide strength, and are resorbable. The addition of DBM or similar compounds into the structure of the implant provides osteoinductivity and osteoconductivity, with ultimate incorporation into the final healed osseous structure; in turn, this allows the implant to facilitate osseous in-growth and increases control of the final healed osseous shape.

In some embodiments, screws, or other similar connective structures or connective compounds, can be utilized to secure the implant in place. The screws for securing the implant can be made of a similar composition as the implant or be made of any material known in the art that is useful in implants, particularly implants of bone structures.

In some embodiments, the scaffold portion is in the form of a mesh or lattice structure, or a combination of both. The mesh or lattice structure maintains its form and can be used to stabilize surrounding bony structures. The scaffold portion can be formed into a customizable, stable form; the shape and structure can also be customized as well to improve its function and overall outcome. The density of the mesh or lattice structure can be
customized as well, making a tighter or looser network as determined to be desirable by the clinician.

In some embodiments, the implant further comprises an autologous bone graft embedded within the scaffold portion. In other embodiments, the implant further comprises bone morphogenic protein (BMP) embedded within the scaffold portion.

The implants of the present invention can be in the form of sheet (plate) of the scaffold structure. A three-dimensional (3D) form may also be adapted to a particular defect or to achieve the desired osseous structural change. A scaffold structure (e.g., lattice-work type structure or similar structure) affords the capability to fill the form with an autologous bone graft or BMP or an additional substrate, should this be desired. The scaffold portion or similar structure may be increased or decreased in thickness in order to decrease or increase porosity of the form, respectively. For customization of the implant, modeling may be employed based on a computerized tomography (CT) scan of the patient.

The implants of the present invention can also be 3D printed if a manufacturer possesses these capabilities. Alternatively, a mold may be fashioned from a compatible substrate and used to fashion the implants.

In another aspect, the present invention provides methods for augmentation, stabilization, or defect reconstruction of bone tissue, comprising applying an implant described herein to a site in need of augmentation, stabilization, or defect reconstruction of bone tissue. In some embodiments, the methods further comprise embedding an autologous bone graft within the scaffold portion. In other embodiments, the methods further comprise embedding BMP within the scaffold portion.

During methods of use the implant can be intraoperatively modified, as the PLA and PGA isomers become malleable when warmed. This allows for further customization. Also, since all components of the implant will be resorbed or incorporated, there is no need for hardware removal in the future.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following examples are offered by way of illustration, not by way of limitation. While specific examples have been provided, the above description is illustrative and not restrictive. Anyone or more of the features of the previously described embodiments can be combined in any manner with one or more features of any other embodiments in the present invention.
Furthermore, many variations of the invention will become apparent to those skilled in the art upon review of the specification.

All publications and patent documents cited in this application are incorporated by reference in pertinent part for all purposes to the same extent as if each individual publication or patent document were so individually denoted.

**Examples**

The methods and implants herein described are further illustrated in the following examples, which are provided by way of illustration and are not intended to be limiting. It will be appreciated that variations in proportions and alternatives in elements of the components shown will be apparent to those skilled in the art and are within the scope of embodiments of the present invention. Theoretical aspects are presented with the understanding that Applicants do not seek to be bound by the theory presented. All parts or amounts, unless otherwise specified, are by weight.

**Example 1**: Implant for stabilization of a long bone (femur).

*Figure 1* shows an implant of the present invention providing stabilization of a long bone.

**Example 2**: Implant for augmentation of a chin.

*Figure 2* shows an implant of the present invention providing chin augmentation.

**Example 3**: Implant for zygoma reconstruction.

*Figure 3* shows an implant of the present invention placed in position for zygoma reconstruction viewed from the face of the skull. *Figure 4* shows the implant shown in Figure 3 viewed from the side of the skull.

**Example 4**: Methods of using the implants of the present invention.

Once the implant has been designed and manufactured, the patient is taken to the operating room and the anatomic area where the implant is to be used is exposed in the standard fashion for augmentation, stabilization, or defect reconstruction.

In the case of bone augmentation, the implant may be fitted against the surface of the bone area to be augmented, by molding or trimming the implant or by other suitable
technique as known in the art. The implant can be secured with screws of a similar composition, depending on the clinical demands of the situation.

In the case of bone stabilization, including but not limited to fracture fixation or buttressing, the implant may be fitted against the surface of the bones once reduction and/or alignment has been achieved. The implant can be secured with screws of a similar composition, depending on the clinical demands of the situation.

In the case of defect reconstruction, a bone defect exists that requires intervening bone placement. In some cases, a 3D form of the implant with a type of lattice structure is utilized. This structure can be filled with autologous cancellous bone graft and/or bone morphogenic protein. The implant can be placed in contact with muscle or fascia to increase the osteoinductive and osteoconductive potential of the implant. The implant can be secured with screws of a similar composition in the standard fashion.

In all cases of use, the implant can be intraoperatively modified as the PLA and PGA isomers become malleable when warmed. This allows for further customization.

As all components of the implant are preferably resorbed or incorporated, there is inherently no need for hardware removal in the future.

**Discussion**

The present invention provides an implant that can be used to buttress, augment, or replace the native bony skeleton. The implant is made from a combination of resorbable malleable material, osteoinductive material, and osteoconductive material, in varying proportions, depending on the specific objectives of its utilization. Not only can the proportion of materials be customized, but the shape and structure can be customized as well to improve its function and overall outcome. The customization of these implants allows for a wide range of applicability to surgical practice, and the use of the resorbable, malleable material allows for further intraoperative adjustment. While all the materials used to form the implants are independently valued, combining them into a single implant increases structural strength and allows incorporation of an implant as part of the osseous structure with time. The implants also provide a patient with a reconstructive alternative for bone replacement with or without autologous bone grafting. As all component materials of the implant are either resorbed or incorporated, there is no need for removal later as with other types of implants.

It is to be appreciated that the foregoing Detailed Description section, and not the Abstract section, is intended to be used to interpret the claims. The Abstract section may set
forth one or more, but not all, exemplary embodiments of the present invention as contemplated by the inventor(s), and thus, is not intended to limit the present invention and the appended claims in any way.

The foregoing description of the specific embodiments should fully reveal the general nature of the invention so that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Since many modifications, variations, and changes in detail can be made to the described preferred embodiment of the invention, it is intended that all matters in the foregoing description and shown in the accompanying drawings be interpreted as illustrative and not in a limiting sense. Thus, the scope of the invention should be determined by the appended claims and their legal equivalents. Moreover, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should similarly be defined only in accordance with the following claims and their equivalents.
CLAIMS

1. An implant for augmentation, stabilization, or defect reconstruction of bone tissue, comprising:
   a scaffold portion structured to provide shape to the implant, the scaffold portion comprising one or more of the following:
   one or more polylactic acid isomer;
   one or more polyglycolic acid isomer; and/or
   allogenic bone material.

2. The implant of claim 1, wherein the allogenic bone material comprises demineralized bone matrix.

3. The implant of claim 1, wherein the scaffold portion is in the form of a mesh structure.

4. The implant of claim 1, wherein the scaffold portion is in the form of a lattice structure.

5. The implant of claim 1, further comprising an autologous bone graft embedded within the scaffold portion.

6. The implant of claim 1, further comprising bone morphogenic protein embedded within the scaffold portion.

7. A method for augmentation, stabilization, or defect reconstruction of bone tissue, comprising:
   applying an implant to a site in need of augmentation, stabilization, or defect reconstruction of bone tissue, wherein the implant comprises:
   a scaffold portion structured to provide shape to the implant, the scaffold portion comprising one or more of the following:
   one or more polylactic acid isomer;
   one or more polyglycolic acid isomer; and/or
allogenic bone material.

8. The method of claim 7, wherein the allogenic bone material comprises demineralized bone matrix.

9. The method of claim 7, wherein the scaffold portion is in the form of a mesh structure.

10. The method of claim 7, wherein the scaffold portion is in the form of a lattice structure.

11. The method of claim 7, further comprising embedding an autologous bone graft within the scaffold portion.

12. The method of claim 7, further comprising embedding bone morphogenic protein within the scaffold portion.
A. CLASSIFICATION OF SUBJECT MATTER
A61L 27/26(2006.01)i, A61F 2/28(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61L 27/26; A61P 43/00; A61F 2/02; A61F 2/46; A61K 9/00; C12N 5/077; A61F 2/44; A61L 27/36; A61K 35/32; A61L 27/38; A61F 2/28

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal) & keywords: bone, scaffold, polylactic acid, polyglycolic acid, allogenic

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 2015-0010607 A1 (LIFENET HEALTH) 8 January 2015 See paragraphs [0035], [0038], [0052]-[0058], [0084].</td>
<td>1-6</td>
</tr>
<tr>
<td>A</td>
<td>US 5948020 A (YOUN, S.J. et al.) 7 September 1999 See entire document.</td>
<td>2-6</td>
</tr>
<tr>
<td>A</td>
<td>US 2010-0172951 A1 (NASIELEWSKI, R.) 8 July 2010 See entire document.</td>
<td>1-6</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

Date of the actual completion of the international search
22 October 2015 (22.10.2015)

Date of mailing of the international search report
28 October 2015 (28.10.2015)

Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
199 Cheongna-ro, Seo-gu, Daejeon Metropolitan City, 35208, Republic of Korea
Facsimile No. +82-42-472-7140

Authorized officer
Han, Mho
Telephone No. +82-42-481-3362

Form PCT/ISA/210 (second sheet) (January 2015)
### Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. □ Claims Nos.: 7-12
   - because they relate to subject matter not required to be searched by this Authority, namely:
     - Claims 7-12 pertain to methods for treatment of the human body and thus relate to a subject-matter which this International Searching Authority is not required under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv) to search.

2. □ Claims Nos.:
   - because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. □ Claims Nos.:
   - because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.

3. □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- □ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- □ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- □ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 2015-0010607 Al</td>
<td>08/01/2015</td>
<td>WO 2013-119873 Al</td>
<td>15/08/2013</td>
</tr>
<tr>
<td>US 8945536 B2</td>
<td>03/02/2015</td>
<td>US 2012-189587 Al</td>
<td>26/07/2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 11-504341 A</td>
<td>20/04/1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 10-0165642 Bl</td>
<td>15/01/1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 10-0180585 Bl</td>
<td>20/03/1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 96-34634 Al</td>
<td>07/11/1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1594423 Bl</td>
<td>07/01/2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012-310352 Al</td>
<td>06/12/2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2004-073563 A2</td>
<td>02/09/2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010-0209387 Al</td>
<td>19/08/2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010-0209878 Al</td>
<td>19/08/2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010-0215617 Al</td>
<td>26/08/2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 8470308 B2</td>
<td>25/06/2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 8470309 B2</td>
<td>25/06/2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 8540978 B2</td>
<td>24/09/2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 8562969 B2</td>
<td>22/10/2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2010-078533 Al</td>
<td>08/07/2010</td>
</tr>
</tbody>
</table>